Dr. Hönle AG (ETR:HNL - Get Free Report) shares fell 0.7% during trading on Friday . The stock traded as low as €9.02 ($9.91) and last traded at €9.04 ($9.93). 767 shares changed hands during mid-day trading, The stock had previously closed at €9.10 ($10.00).
Dr. Hönle Trading Down 0.7 %
The firm has a market cap of $54.78 million, a P/E ratio of -9.93, a price-to-earnings-growth ratio of -0.39 and a beta of 1.45. The firm has a fifty day simple moving average of €11.73 and a 200-day simple moving average of €16.03. The company has a debt-to-equity ratio of 59.06, a current ratio of 1.98 and a quick ratio of 0.85.
About Dr. Hönle
(
Get Free Report)
Dr. Hönle AG engages in the supply of industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, automotive, optics and opto-electronics, medical technology, and glass processing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Hönle, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Hönle wasn't on the list.
While Dr. Hönle currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
